Anixa Biosciences CEO presents at Nasdaq-LD Micro SF Summit
ANIX•Clinical program updates
Update expected on its Phase 1 CAR-T program in ovarian cancer, run with Moffitt Cancer Center, with no dose-limiting toxicities reported.
Discussion to cover its Phase 1 breast cancer vaccine trial at Cleveland Clinic, funded by the U.S. Department of Defense, which met primary endpoints.
Conference presentation and breakout session
Anixa Biosciences will present at the Nasdaq & LD Micro Inaugural SF Summit on Sept. 9, 2026.
The talk is scheduled for 3:40 PM PT at Nasdaq’s San Francisco headquarters, followed by a breakout session.
